{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:06:37Z","timestamp":1790193997853,"version":"4.1.0"},"publisher-location":"Berlin, Heidelberg","reference-count":110,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/164_2026_858","type":"book-chapter","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:38:26Z","timestamp":1790192306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Opportunities and Challenges for PBPK Modelling in Specific Populations: Considerations for Paediatrics, Pregnancy, Lactation, Ethnic Differences, and Organ Impairment"],"prefix":"10.1007","author":[{"given":"Xian","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"El-Khateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udoamaka","family":"Ezuruike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"11","key":"858_CR1","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s40262-024-01432-w","volume":"63","author":"K Abduljalil","year":"2024","unstructured":"Abduljalil K, Faisal M (2024) Impact of Milk pH and fat content on the prediction of Milk-to-plasma ratio: knowledge gap and considerations for lactation study design and interpretation. Clin Pharmacokinet 63(11):1561\u20131572","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"858_CR2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/11597440-000000000-00000","volume":"51","author":"K Abduljalil","year":"2012","unstructured":"Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H (2012) Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet 51(6):365\u2013396","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"858_CR3","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40262-017-0618-1","volume":"57","author":"K Abduljalil","year":"2018","unstructured":"Abduljalil K, Johnson TN, Rostami-Hodjegan A (2018) Fetal physiologically-based pharmacokinetic models: systems information on fetal biometry and gross composition. Clin Pharmacokinet 57(9):1149\u20131171","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"858_CR4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40262-018-0685-y","volume":"58","author":"K Abduljalil","year":"2019","unstructured":"Abduljalil K, Jamei M, Johnson TN (2019) Fetal physiologically based pharmacokinetic models: systems information on the growth and composition of fetal organs. Clin Pharmacokinet 58(2):235\u2013262","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"858_CR5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40262-019-00825-6","volume":"59","author":"K Abduljalil","year":"2020","unstructured":"Abduljalil K, Pan X, Pansari A, Jamei M, Johnson TN (2020a) A preterm physiologically based pharmacokinetic model. Part I: physiological parameters and model building. Clin Pharmacokinet 59(4):485\u2013500","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"858_CR6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40262-019-00827-4","volume":"59","author":"K Abduljalil","year":"2020","unstructured":"Abduljalil K, Pan X, Pansari A, Jamei M, Johnson TN (2020b) Preterm physiologically based pharmacokinetic model. Part II: applications of the model to predict drug pharmacokinetics in the preterm population. Clin Pharmacokinet 59(4):501\u2013518","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"858_CR7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40262-019-00836-3","volume":"59","author":"K Abduljalil","year":"2020","unstructured":"Abduljalil K, Jamei M, Johnson TN (2020c) Fetal physiologically based pharmacokinetic models: systems information on fetal blood components and binding proteins. Clin Pharmacokinet 59(5):629\u2013642","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"858_CR8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10928-020-09711-2","volume":"47","author":"K Abduljalil","year":"2020","unstructured":"Abduljalil K, Pansari A, Jamei M (2020d) Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy. J Pharmacokinet Pharmacodyn 47(4):361\u2013383","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"858_CR9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40262-020-00973-0","volume":"60","author":"K Abduljalil","year":"2021","unstructured":"Abduljalil K, Pan X, Clayton R, Johnson TN, Jamei M (2021) Fetal physiologically based pharmacokinetic models: systems information on fetal cardiac output and its distribution to different organs during development. Clin Pharmacokinet 60(6):741\u2013757","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"858_CR10","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40262-021-01103-0","volume":"61","author":"K Abduljalil","year":"2022","unstructured":"Abduljalil K, Pansari A, Ning J, Jamei M (2022) Prediction of maternal and fetal acyclovir, Emtricitabine, lamivudine, and metformin concentrations during pregnancy using a physiologically based pharmacokinetic modeling approach. Clin Pharmacokinet 61(5):725\u2013748","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"858_CR11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12936-024-05112-9","volume":"23","author":"N Abla","year":"2024","unstructured":"Abla N, Marrast AC, Jambert E, Richardson N, Duparc S, Almond L et al (2024) Addressing health equity for breastfeeding women: primaquine for Plasmodium vivax radical cure. Malar J 23(1):287","journal-title":"Malar J"},{"issue":"12","key":"858_CR12","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/jcph.6148","volume":"64","author":"K Allegaert","year":"2024","unstructured":"Allegaert K (2024) Physiologically based pharmacokinetic modeling to assess the impact of pathophysiological changes in neonates: strengths, weaknesses, and next steps. J Clin Pharmacol 64(12):1606\u20131609","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"858_CR13","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/psp4.13311","volume":"14","author":"LM Almond","year":"2025","unstructured":"Almond LM, Abduljalil K, Pansari A, Kusmider B, Jones HM, Rowland Yeo K et al (2025) PBPK-led assessment of antimalarial drug concentrations in breastmilk: a strategy for optimal use of prediction methods to guide decision making in an understudied population. CPT Pharmacometrics Syst Pharmacol 14(4):738\u2013750","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"858_CR14","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.xphs.2024.02.024","volume":"113","author":"J Al-Qassabi","year":"2024","unstructured":"Al-Qassabi J, Tan SPF, Phonboon P, Galetin A, Rostami-Hodjegan A, Scotcher D (2024) Facing the facts of altered plasma protein binding: do current models correctly predict changes in fraction unbound in special populations? J Pharm Sci 113(6):1664\u20131673","journal-title":"J Pharm Sci"},{"issue":"Suppl 1","key":"858_CR15","first-page":"S42","volume":"59","author":"J Badee","year":"2019","unstructured":"Badee J, Qiu N, Collier AC, Takahashi RH, Forrest WF, Parrott N et al (2019) Characterization of the ontogeny of hepatic UDP-glucuronosyltransferase enzymes based on Glucuronidation activity measured in human liver Microsomes. J Clin Pharmacol 59(Suppl 1):S42\u2013S55","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"858_CR16","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40262-013-0089-y","volume":"52","author":"ZE Barter","year":"2013","unstructured":"Barter ZE, Tucker GT, Rowland-Yeo K (2013) Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin Pharmacokinet 52(12):1085\u20131100","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"858_CR17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/cpt.1109","volume":"105","author":"DK Bhatt","year":"2019","unstructured":"Bhatt DK, Mehrotra A, Gaedigk A, Chapa R, Basit A, Zhang H et al (2019) Age- and genotype-dependent variability in the protein abundance and activity of six major uridine diphosphate-glucuronosyltransferases in human liver. Clin Pharmacol Ther 105(1):131\u2013141","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"858_CR18","first-page":"S104","volume":"59","author":"Y Bi","year":"2019","unstructured":"Bi Y, Liu J, Li L, Yu J, Bhattaram A, Bewernitz M et al (2019) Role of model-informed drug development in pediatric drug development, regulatory evaluation, and labeling. J Clin Pharmacol 59(Suppl 1):S104\u2013SS11","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 1","key":"858_CR19","first-page":"S60","volume":"61","author":"Y Bi","year":"2021","unstructured":"Bi Y, Liu J, Li F, Yu J, Bhattaram A, Bewernitz M et al (2021) Model-informed drug development in pediatric dose selection. J Clin Pharmacol 61(Suppl 1):S60\u2013SS9","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"858_CR20","first-page":"17","volume":"2","author":"FV Bupsilondingen","year":"2014","unstructured":"Bupsilondingen FV, Gonzalez D, Tucker AN, Derendorf H (2014) Relevance of liver failure for anti-infective agents: from pharmacokinetic alterations to dosage adjustments. Ther Adv Infect Dis 2(1):17\u201342","journal-title":"Ther Adv Infect Dis"},{"issue":"5","key":"858_CR21","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/cpt.1516","volume":"106","author":"KWK Cheung","year":"2019","unstructured":"Cheung KWK, van Groen BD, Spaans E, van Borselen MD, de Bruijn A, Simons-Oosterhuis Y et al (2019) A comprehensive analysis of ontogeny of renal drug transporters: mRNA analyses, quantitative proteomics, and localization. Clin Pharmacol Ther 106(5):1083\u20131092","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"858_CR22","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/jcph.2452","volume":"64","author":"M Codaccioni","year":"2024","unstructured":"Codaccioni M, Southall RL, Dinh J, Johnson TN (2024) Prediction of pediatric pharmacokinetics for CYP3A4 metabolized drugs: comparison of the performance of two hepatic ontogeny within a physiologically based pharmacokinetic model. J Clin Pharmacol 64(9):1083\u20131094","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"858_CR23","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3109\/00498254.2011.560294","volume":"41","author":"HE Cubitt","year":"2011","unstructured":"Cubitt HE, Yeo KR, Howgate EM, Rostami-Hodjegan A, Barter ZE (2011) Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica 41(8):623\u2013638","journal-title":"Xenobiotica"},{"issue":"9","key":"858_CR24","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/psp4.13202","volume":"13","author":"L Curry","year":"2024","unstructured":"Curry L, Alrubia S, Bois FY, Clayton R, El-Khateeb E, Johnson TN et al (2024) A guide to developing population files for physiologically-based pharmacokinetic modeling in the Simcyp simulator. CPT Pharmacometrics Syst Pharmacol 13(9):1429\u20131447","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"11","key":"858_CR25","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s40262-017-0539-z","volume":"56","author":"A Dallmann","year":"2017","unstructured":"Dallmann A, Ince I, Meyer M, Willmann S, Eissing T, Hempel G (2017) Gestation-specific changes in the anatomy and physiology of healthy pregnant women: An extended repository of model parameters for physiologically based pharmacokinetic modeling in pregnancy. Clin Pharmacokinet 56(11):1303\u20131330","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"858_CR26","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/cpt.1084","volume":"104","author":"A Dallmann","year":"2018","unstructured":"Dallmann A, Pfister M, van den Anker J, Eissing T (2018) Physiologically based pharmacokinetic modeling in pregnancy: a systematic review of published models. Clin Pharmacol Ther 104(6):1110\u20131124","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"858_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jpm8010001","volume":"8","author":"AK Daly","year":"2017","unstructured":"Daly AK, Rettie AE, Fowler DM, Miners JO (2017) Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med 8(1):1","journal-title":"J Pers Med"},{"issue":"1","key":"858_CR28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s13318-024-00924-1","volume":"50","author":"M Darwish","year":"2025","unstructured":"Darwish M, Marbury TC, Nunez R, Youakim JM, An D, Darling I et al (2025) Physiologically-based pharmacokinetic modeling of Trofinetide in moderate renal impairment for phase 1 clinical study dose selection with model validation. Eur J Drug Metab Pharmacokinet 50(1):23\u201338","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"858_CR29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/picr.PICR_6_20","volume":"11","author":"M Desai","year":"2020","unstructured":"Desai M (2020) Recruitment and retention of participants in clinical studies: critical issues and challenges. Perspect Clin Res 11(2):51\u201353","journal-title":"Perspect Clin Res"},{"issue":"11","key":"858_CR30","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.3390\/pharmaceutics15112579","volume":"15","author":"J Dinh","year":"2023","unstructured":"Dinh J, Johnson TN, Grimstein M, Lewis T (2023) Physiologically based pharmacokinetics modeling in the neonatal population-current advances, challenges, and opportunities. Pharmaceutics 15(11):2579","journal-title":"Pharmaceutics"},{"issue":"5","key":"858_CR31","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/cpt.1301","volume":"105","author":"M Drozdzik","year":"2019","unstructured":"Drozdzik M, Busch D, Lapczuk J, M\u00fcller J, Ostrowski M, Kurzawski M et al (2019) Protein abundance of clinically relevant drug transporters in the human liver and intestine: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 105(5):1204\u20131212","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"858_CR32","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1124\/dmd.120.000152","volume":"48","author":"E El-Khateeb","year":"2020","unstructured":"El-Khateeb E, Achour B, Scotcher D, Al-Majdoub ZM, Athwal V, Barber J et al (2020) Scaling factors for clearance in adult liver cirrhosis. Drug Metab Dispos 48(12):1271\u20131282","journal-title":"Drug Metab Dispos"},{"key":"858_CR33","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1021\/acs.molpharmaceut.1c00462","volume":"18","author":"E El-Khateeb","year":"2021","unstructured":"El-Khateeb E, Achour B, Al-Majdoub Z, Barber J, Rostami-Hodjegan A (2021a) Non-uniformity of changes in drug-metabolizing enzymes and transporters in liver cirrhosis: implications for drug dosage adjustment. Mol Pharm 18:3563","journal-title":"Mol Pharm"},{"key":"858_CR34","doi-asserted-by":"publisher","unstructured":"El-Khateeb E, Al-Majdoub ZM, Rostami-Hodjegan A, Barber J, Achour B (2021b) Proteomic quantification of changes in abundance of drug-metabolizing enzymes and drug transporters in human liver cirrhosis: different methods, similar outcomes. Drug Metab Dispos. https:\/\/doi.org\/10.1124\/dmd.121.000484","DOI":"10.1124\/dmd.121.000484"},{"issue":"4","key":"858_CR35","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/apt.16489","volume":"54","author":"E El-Khateeb","year":"2021","unstructured":"El-Khateeb E, Darwich AS, Achour B, Athwal V, Rostami-Hodjegan A (2021c) Review article: time to revisit child-Pugh score as the basis for predicting drug clearance in hepatic impairment. Aliment Pharmacol Ther 54(4):388\u2013401","journal-title":"Aliment Pharmacol Ther"},{"key":"858_CR36","volume-title":"Use TICoHoTRfRoPfH","author":"EMEA","year":"1998","unstructured":"EMEA (1998) ICH: E 5 (R1): Ethnic factors in the acceptability of foreign clinical data. In: Use TICoHoTRfRoPfH. London"},{"issue":"10","key":"858_CR37","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/psp4.70068","volume":"14","author":"U Ezuruike","year":"2025","unstructured":"Ezuruike U, Dinh J, El-Khateeb E, Blenkinsop A, Hatley O, Gardner I (2025a) Development and verification of virtual population models for predicting drug pharmacokinetics in ethnic north American populations. CPT Pharmacometrics Syst Pharmacol 14(10):1598\u20131615","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"858_CR38","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/bcp.15982","volume":"91","author":"U Ezuruike","year":"2025","unstructured":"Ezuruike U, Curry L, Hatley O, Gardner I (2025b) Exploring the impact of ethnicity on drug pharmacokinetics using PBPK models: a case study with lansoprazole in Japanese subjects. Br J Clin Pharmacol 91(4):1016\u20131030","journal-title":"Br J Clin Pharmacol"},{"key":"858_CR39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejpb.2019.02.001","volume":"137","author":"L Freerks","year":"2019","unstructured":"Freerks L, Papadatou Soulou E, Batchelor H, Klein S (2019) A review of GI conditions critical to oral drug absorption in malnourished children. Eur J Pharm Biopharm 137:9\u201322","journal-title":"Eur J Pharm Biopharm"},{"issue":"1\u20132","key":"858_CR40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijpharm.2011.04.069","volume":"415","author":"AC Freire","year":"2011","unstructured":"Freire AC, Basit AW, Choudhary R, Piong CW, Merchant HA (2011) Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery. Int J Pharm 415(1\u20132):15\u201328","journal-title":"Int J Pharm"},{"issue":"4","key":"858_CR41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1208\/s12248-022-00722-0","volume":"24","author":"KL Gill","year":"2022","unstructured":"Gill KL, Jones HM (2022) Opportunities and challenges for PBPK model of mAbs in paediatrics and pregnancy. AAPS J 24(4):72","journal-title":"AAPS J"},{"issue":"1","key":"858_CR42","doi-asserted-by":"crossref","first-page":"20240565","DOI":"10.1098\/rsbl.2024.0565","volume":"21","author":"D Giofre","year":"2025","unstructured":"Giofre D, Geary DC, Halsey LG (2025) The sexy and formidable male body: men\u2019s height and weight are conditfion-dependent, sexually selected traits. Biol Lett 21(1):20240565","journal-title":"Biol Lett"},{"issue":"1","key":"858_CR43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.xphs.2018.10.033","volume":"108","author":"M Grimstein","year":"2019","unstructured":"Grimstein M, Yang Y, Zhang X, Grillo J, Huang SM, Zineh I et al (2019) Physiologically based pharmacokinetic modeling in regulatory science: An update from the U.S. Food and Drug Administration\u2019s Office of Clinical Pharmacology. J Pharm Sci 108(1):21\u201325","journal-title":"J Pharm Sci"},{"issue":"Suppl 1","key":"858_CR44","doi-asserted-by":"crossref","first-page":"s55","DOI":"10.1590\/1806-9282.66.s1.55","volume":"66","author":"MAA Hazin","year":"2020","unstructured":"Hazin MAA (2020) Anemia in chronic kidney disease. Rev Assoc Med Bras 66(Suppl 1):s55\u2013ss8","journal-title":"Rev Assoc Med Bras"},{"key":"858_CR45","doi-asserted-by":"publisher","unstructured":"Heimbach T, Chen Y, Chen J, Dixit V, Parrott N, Peters SA et al (2020) Physiologically-based pharmacokinetic modeling in renal and hepatic impairment populations: a pharmaceutical industry perspective. Clinical Pharmacol Ther. https:\/\/doi.org\/10.1002\/cpt.2125","DOI":"10.1002\/cpt.2125"},{"key":"858_CR46","doi-asserted-by":"crossref","first-page":"1507551","DOI":"10.3389\/fphar.2024.1507551","volume":"15","author":"S Heo","year":"2024","unstructured":"Heo S, Butler AS, Stamouli Simoncioni M, Moult S, Malamatari M, Kerwash E et al (2024) Evaluation of mathematical models for predicting medicine distribution into breastmilk \u2013 considering biological heterogeneity. Front Pharmacol 15:1507551","journal-title":"Front Pharmacol"},{"issue":"3","key":"858_CR47","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/cpt.3705","volume":"118","author":"E Hong","year":"2025","unstructured":"Hong E, Hebert MF, Fay E, Turner G, Eshaghian P, Trimble A et al (2025) Predicting maternal and fetal exposures of Elexacaftor-Tezacaftor-Ivacaftor during pregnancy through physiologically based pharmacokinetic models. Clin Pharmacol Ther 118(3):622\u2013631","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"858_CR48","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/00498250600683262","volume":"36","author":"S Inoue","year":"2006","unstructured":"Inoue S, Howgate EM, Rowland-Yeo K, Shimada T, Yamazaki H, Tucker GT et al (2006) Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences. Xenobiotica 36(6):499\u2013513","journal-title":"Xenobiotica"},{"issue":"Suppl 1","key":"858_CR49","first-page":"S83","volume":"61","author":"TN Johnson","year":"2021","unstructured":"Johnson TN, Ke AB (2021) Physiologically based pharmacokinetic modeling and Allometric scaling in pediatric drug development: where do we draw the line? J Clin Pharmacol 61(Suppl 1):S83\u2013S93","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"858_CR50","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","volume":"45","author":"TN Johnson","year":"2006","unstructured":"Johnson TN, Rostami-Hodjegan A, Tucker GT (2006) Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 45(9):931\u2013956","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"858_CR51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11318160-000000000-00000","volume":"49","author":"TN Johnson","year":"2010","unstructured":"Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A (2010) A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet 49(3):189\u2013206","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"858_CR52","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/bdd.1899","volume":"35","author":"TN Johnson","year":"2014","unstructured":"Johnson TN, Zhou D, Bui KH (2014) Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents. Biopharm Drug Dispos 35(6):341\u2013352","journal-title":"Biopharm Drug Dispos"},{"issue":"7","key":"858_CR53","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1124\/dmd.115.068643","volume":"44","author":"TN Johnson","year":"2016","unstructured":"Johnson TN, Jamei M, Rowland-Yeo K (2016) How does in vivo biliary elimination of drugs change with age? Evidence from in vitro and clinical data using a systems pharmacology approach. Drug Metab Dispos 44(7):1090\u20131098","journal-title":"Drug Metab Dispos"},{"key":"858_CR54","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejps.2018.01.009","volume":"115","author":"TN Johnson","year":"2018","unstructured":"Johnson TN, Bonner JJ, Tucker GT, Turner DB, Jamei M (2018) Development and applications of a physiologically-based model of paediatric oral drug absorption. Eur J Pharm Sci 115:57\u201367","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"858_CR55","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/psp4.12678","volume":"10","author":"TN Johnson","year":"2021","unstructured":"Johnson TN, Small BG, Berglund EG, Rowland YK (2021a) A best practice framework for applying physiologically-based pharmacokinetic modeling to pediatric drug development. CPT Pharmacometrics Syst Pharmacol 10(9):967\u2013972","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"858_CR56","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/bcp.14528","volume":"87","author":"TN Johnson","year":"2021","unstructured":"Johnson TN, Abduljalil K, Nicolas JM, Muglia P, Chanteux H, Nicolai J et al (2021b) Use of a physiologically based pharmacokinetic-pharmacodynamic model for initial dose prediction and escalation during a paediatric clinical trial. Br J Clin Pharmacol 87(3):1378\u20131389","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"858_CR57","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1124\/dmd.123.001270","volume":"51","author":"TN Johnson","year":"2023","unstructured":"Johnson TN, Howgate EM, de Wildt SN, Turner MA, Rowland Yeo K (2023a) Use of developmental midazolam and 1-Hydroxymidazolam data with pediatric physiologically based modeling to assess cytochrome P450 3A4 and uridine diphosphate Glucuronosyl transferase 2B4 ontogeny in vivo. Drug Metab Dispos 51(8):1035\u20131045","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"858_CR58","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/jcph.2317","volume":"63","author":"TN Johnson","year":"2023","unstructured":"Johnson TN, Abduljalil K, Pan X, Emoto C (2023b) Development and verification of a Japanese pediatric physiologically based pharmacokinetic model with emphasis on drugs eliminated by cytochrome P450 or renal excretion. J Clin Pharmacol 63(10):1156\u20131168","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"858_CR59","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1038\/s41598-023-29798-0","volume":"13","author":"S Khalid","year":"2023","unstructured":"Khalid S, Rasool MF, Masood I, Imran I, Saeed H, Ahmad T et al (2023) Application of a physiologically based pharmacokinetic model in predicting captopril disposition in children with chronic kidney disease. Sci Rep 13(1):2697","journal-title":"Sci Rep"},{"issue":"8","key":"858_CR60","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1124\/dmd.119.086462","volume":"47","author":"MK Ladumor","year":"2019","unstructured":"Ladumor MK, Bhatt DK, Gaedigk A, Sharma S, Thakur A, Pearce RE et al (2019) Ontogeny of hepatic sulfotransferases and prediction of age-dependent fractional contribution of Sulfation in acetaminophen metabolism. Drug Metab Dispos 47(8):818\u2013831","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"858_CR61","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2165\/00003088-199732010-00002","volume":"32","author":"YW Lam","year":"1997","unstructured":"Lam YW, Banerji S, Hatfield C, Talbert RL (1997) Principles of drug administration in renal insufficiency. Clin Pharmacokinet 32(1):30\u201357","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"858_CR62","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0002-9343(77)90397-7","volume":"62","author":"G Levy","year":"1977","unstructured":"Levy G (1977) Pharmacokinetics in renal disease. Am J Med 62(4):461\u2013465","journal-title":"Am J Med"},{"issue":"7","key":"858_CR63","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40262-019-00737-5","volume":"58","author":"GF Li","year":"2019","unstructured":"Li GF, Zheng QS, Yu Y, Zhong W, Zhou HH, Qiu F et al (2019) Impact of ethnicity-specific hepatic microsomal scaling factor, liver weight, and cytochrome P450 (CYP) 1A2 content on physiologically based prediction of CYP1A2-mediated pharmacokinetics in young and elderly Chinese adults. Clin Pharmacokinet 58(7):927\u2013941","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"858_CR64","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/psp4.13254","volume":"14","author":"S Li","year":"2025","unstructured":"Li S, Ye X, Wang Q, Cheng Z, Liu F, Xie F (2025) Is the GFR-based scaling approach adequate for predicting pediatric renal clearance of drugs with passive tubular reabsorption? Insights from PBPK modeling. CPT Pharmacometrics Syst Pharmacol 14(1):152\u2013163","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"11","key":"858_CR65","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00228-004-0852-y","volume":"60","author":"M Martin-Facklam","year":"2005","unstructured":"Martin-Facklam M, Rengelshausen J, Tayrouz Y, Ketabi-Kiyanvash N, Lindenmaier H, Schneider V et al (2005) Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management? Eur J Clin Pharmacol 60(11):807\u2013811","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"858_CR66","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1124\/dmd.114.056929","volume":"42","author":"MG Mooij","year":"2014","unstructured":"Mooij MG, Schwarz UI, de Koning BA, Leeder JS, Gaedigk R, Samsom JN et al (2014) Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters. Drug Metab Dispos 42(8):1268\u20131274","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"858_CR67","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-019-0340-z","volume":"21","author":"JM Nicolas","year":"2019","unstructured":"Nicolas JM, de Lange ECM (2019) Mind the gaps: ontogeny of human brain P-gp and its impact on drug toxicity. AAPS J 21(4):67","journal-title":"AAPS J"},{"issue":"11","key":"858_CR68","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/psp4.13251","volume":"13","author":"J Ning","year":"2024","unstructured":"Ning J, Pansari A, Rowland Yeo K, Heikkinen AT, Waitt C, Almond LM (2024) Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women. CPT Pharmacometrics Syst Pharmacol 13(11):1924\u20131938","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"858_CR69","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/sdi.12374","volume":"28","author":"TD Nolin","year":"2015","unstructured":"Nolin TD (2015) A synopsis of clinical pharmacokinetic alterations in advanced CKD. Semin Dial 28(4):325\u2013329","journal-title":"Semin Dial"},{"issue":"1","key":"858_CR70","first-page":"1","volume":"21","author":"A Omar Abdulhameed","year":"2017","unstructured":"Omar Abdulhameed A, Mohammad Kowser M, Raman V (2017) Drug metabolism in the liver. Clin Liver Dis 21(1):1\u201320","journal-title":"Clin Liver Dis"},{"issue":"3","key":"858_CR71","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/clpt.2008.216","volume":"85","author":"R Orlando","year":"2009","unstructured":"Orlando R, De Martin S, Pegoraro P, Quintieri L, Palatini P (2009) Irreversible CYP3A inhibition accompanied by plasma protein-binding displacement: a comparative analysis in subjects with normal and impaired liver function. Clin Pharmacol Ther 85(3):319\u2013326","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"858_CR72","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/cpt.2912","volume":"114","author":"X Pan","year":"2023","unstructured":"Pan X, Rowland Yeo K (2023) Physiologically based pharmacokinetic modeling to determine the impact of CYP2B6 genotype on Efavirenz exposure in children, mothers and breastfeeding infants. Clin Pharmacol Ther 114(1):182\u2013191","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"858_CR73","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10928-025-09969-4","volume":"52","author":"X Pan","year":"2025","unstructured":"Pan X, Rowland Yeo K (2025) Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine in lactation. J Pharmacokinet Pharmacodyn 52(2):22","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"858_CR74","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/psp4.13090","volume":"13","author":"X Pan","year":"2024","unstructured":"Pan X, Abduljalil K, Almond LM, Pansari A, Yeo KR (2024) Supplementing clinical lactation studies with PBPK modeling to inform drug therapy in lactating mothers: prediction of primaquine exposure as a case example. CPT Pharmacometrics Syst Pharmacol 13(3):386\u2013395","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"11","key":"858_CR75","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/psp4.13232","volume":"13","author":"A Pansari","year":"2024","unstructured":"Pansari A, Pan X, Almond LM, Rowland-Yeo K (2024) A tutorial on physiologically based pharmacokinetic approaches in lactation research. CPT Pharmacometrics Syst Pharmacol 13(11):1841\u20131855","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"858_CR76","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2023.01.016","volume":"259","author":"A Patel","year":"2023","unstructured":"Patel A, Sushko K, Mazer-Amirshahi M, Pfuma Fletcher E, Fusch G, Chan O et al (2023) Availability of safe and effective therapeutic options to pregnant and lactating individuals following the United States Food and Drug Administration pregnancy and lactation labeling rule. J Pediatr 259:113342","journal-title":"J Pediatr"},{"issue":"3","key":"858_CR77","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cpt.3525","volume":"117","author":"P Paul","year":"2025","unstructured":"Paul P, Colin PJ, Musuamba Tshinanu F, Versantvoort C, Manolis E, Blake K (2025) Current use of physiologically based pharmacokinetic modeling in new medicinal product approvals at EMA. Clin Pharmacol Ther 117(3):808\u2013817","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"858_CR78","first-page":"713","volume":"41","author":"S Pernia","year":"2016","unstructured":"Pernia S, DeMaagd G (2016) The new pregnancy and lactation labeling rule. P T 41(11):713\u2013715","journal-title":"P T"},{"issue":"7","key":"858_CR79","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1124\/dmd.118.080523","volume":"46","author":"B Prasad","year":"2018","unstructured":"Prasad B, Bhatt DK, Johnson K, Chapa R, Chu X, Salphati L et al (2018) Abundance of phase 1 and 2 drug-metabolizing enzymes in alcoholic and hepatitis C cirrhotic livers: a quantitative targeted proteomics study. Drug Metab Dispos 46(7):943\u2013952","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"858_CR80","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jmoldx.2019.04.003","volume":"21","author":"VM Pratt","year":"2019","unstructured":"Pratt VM, Cavallari LH, Del Tredici AL, Hachad H, Ji Y, Moyer AM et al (2019) Recommendations for clinical CYP2C9 genotyping allele selection: a joint recommendation of the Association for Molecular Pathology and College of American pathologists. J Mol Diagn 21(5):746\u2013755","journal-title":"J Mol Diagn"},{"issue":"12","key":"858_CR81","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/psp4.13241","volume":"13","author":"L Qian","year":"2024","unstructured":"Qian L, Wang Z, Paine MF, Chan ECY, Zhou Z (2024) Application of physiologically-based pharmacokinetic modeling to inform dosing decisions for geriatric patients. CPT Pharmacometrics Syst Pharmacol 13(12):2031\u20132035","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"858_CR82","doi-asserted-by":"crossref","DOI":"10.1038\/srep27966","volume":"6","author":"G Redlarski","year":"2016","unstructured":"Redlarski G, Palkowski A, Krawczuk M (2016) Body surface area formulae: an alarming ambiguity. Sci Rep 6:27966","journal-title":"Sci Rep"},{"key":"858_CR83","unstructured":"Rowland Yeo KJ (2022) T.N. Advancing pediatric drug development and regulatory acceptance using Simcyp PBPK: from Birth to Young Adult 2022. Available from: https:\/\/www.certara.com\/app\/uploads\/2022\/03\/WP_Adv-Pediatric-Drug-Dev_FNL.pdf"},{"issue":"8","key":"858_CR84","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/jcph.100","volume":"53","author":"F Salem","year":"2013","unstructured":"Salem F, Johnson TN, Barter ZE, Leeder JS, Rostami-Hodjegan A (2013) Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions. J Clin Pharmacol 53(8):857\u2013865","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"858_CR85","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/psp4.12798","volume":"11","author":"F Salem","year":"2022","unstructured":"Salem F, Small BG, Johnson TN (2022) Development and application of a pediatric mechanistic kidney model. CPT Pharmacometrics Syst Pharmacol 11(7):854\u2013866","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"858_CR86","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3390\/jcm13051428","volume":"13","author":"D Sanchez-Ospina","year":"2024","unstructured":"Sanchez-Ospina D, Mas-Fontao S, Gracia-Iguacel C, Avello A, Gonzalez de Rivera M, Mujika-Marticorena M et al (2024) Displacing the burden: a review of protein-bound uremic toxin clearance strategies in chronic kidney disease. J Clin Med 13(5):1428","journal-title":"J Clin Med"},{"issue":"3","key":"858_CR87","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/cpt.2333","volume":"110","author":"K Sangkuhl","year":"2021","unstructured":"Sangkuhl K, Claudio-Campos K, Cavallari LH, Agundez JAG, Whirl-Carrillo M, Duconge J et al (2021) PharmVar GeneFocus: CYP2C9. Clin Pharmacol Ther 110(3):662\u2013676","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"858_CR88","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/psp4.12203","volume":"6","author":"M Sato","year":"2017","unstructured":"Sato M, Ochiai Y, Kijima S, Nagai N, Ando Y, Shikano M et al (2017) Quantitative modeling and simulation in PMDA: a Japanese regulatory perspective. CPT Pharmacometrics Syst Pharmacol 6(7):413\u2013415","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"858_CR89","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/pr.2015.237","volume":"79","author":"PK Sethi","year":"2016","unstructured":"Sethi PK, White CA, Cummings BS, Hines RN, Muralidhara S, Bruckner JV (2016) Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin. Pediatr Res 79(3):409\u2013415","journal-title":"Pediatr Res"},{"issue":"3","key":"858_CR90","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/cpt.2777","volume":"113","author":"BG Small","year":"2023","unstructured":"Small BG, Johnson TN, Rowland Yeo K (2023) Another step toward qualification of pediatric physiologically based pharmacokinetic models to facilitate inclusivity and diversity in pediatric clinical studies. Clin Pharmacol Ther 113(3):735\u2013745","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"858_CR91","first-page":"2229","volume":"12","author":"K Somnay","year":"2024","unstructured":"Somnay K, Wadgaonkar P, Sridhar N, Roshni P, Rao N, Wadgaonkar R (2024) Liver fibrosis leading to cirrhosis: basic mechanisms and clinical perspectives. Biomedicine 12(10):2229","journal-title":"Biomedicine"},{"issue":"1","key":"858_CR92","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-025-01151-5","volume":"28","author":"RL Southall","year":"2025","unstructured":"Southall RL, Dinh J, Pan X, Ning J, Johnson TN (2025) Development, verification, and application of a Chinese pediatric physiologically based pharmacokinetic model: emphasis on CYP metabolism and renal elimination. AAPS J 28(1):17","journal-title":"AAPS J"},{"key":"858_CR93","volume":"200","author":"Z Sun","year":"2024","unstructured":"Sun Z, Zhao N, Zhao X, Wang Z, Liu Z, Cui Y (2024) Application of physiologically based pharmacokinetic modeling of novel drugs approved by the U.S. food and drug administration. Eur J Pharm Sci 200:106838","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"858_CR94","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/psp4.13243","volume":"13","author":"C Sychterz","year":"2024","unstructured":"Sychterz C, Shen H, Zhang Y, Sinz M, Rostami-Hodjegan A, Schmidt BJ et al (2024) A close examination of BCRP\u2019s role in lactation and methods for predicting drug distribution into milk. CPT Pharmacometrics Syst Pharmacol 13(11):1856\u20131869","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"858_CR95","first-page":"170","volume":"16","author":"C Tayman","year":"2011","unstructured":"Tayman C, Rayyan M, Allegaert K (2011) Neonatal pharmacology: extensive interindividual variability despite limited size. J Pediatr Pharmacol Ther 16(3):170\u2013184","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"3","key":"858_CR96","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/jcph.585","volume":"56","author":"VV Upreti","year":"2016","unstructured":"Upreti VV, Wahlstrom JL (2016) Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J Clin Pharmacol 56(3):266\u2013283","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 10","key":"858_CR97","first-page":"S10","volume":"58","author":"J van den Anker","year":"2018","unstructured":"van den Anker J, Reed MD, Allegaert K, Kearns GL (2018) Developmental changes in pharmacokinetics and pharmacodynamics. J Clin Pharmacol 58(Suppl 10):S10\u2013S25","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"858_CR98","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF02395213","volume":"27","author":"RK Verbeeck","year":"1984","unstructured":"Verbeeck RK, Cardinal JA, Wallace SM (1984) Effect of age and sex on the plasma binding of acidic and basic drugs. Eur J Clin Pharmacol 27(1):91\u201397","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"858_CR99","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/cpt.1864","volume":"108","author":"LFM Verscheijden","year":"2020","unstructured":"Verscheijden LFM, van der Zanden TM, van Bussel LPM, de Hoop-Sommen M, Russel FGM, Johnson TN et al (2020) Chloroquine dosing recommendations for pediatric COVID-19 supported by modeling and simulation. Clin Pharmacol Ther 108(2):248\u2013252","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"858_CR100","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1124\/dmd.116.071050","volume":"44","author":"L Wang","year":"2016","unstructured":"Wang L, Collins C, Kelly EJ, Chu X, Ray AS, Salphati L et al (2016) Transporter expression in liver tissue from subjects with alcoholic or hepatitis C cirrhosis quantified by targeted quantitative proteomics. Drug Metab Dispos 44(11):1752\u20131758","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"858_CR101","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/cpt.676","volume":"101","author":"J Wang","year":"2017","unstructured":"Wang J, Johnson T, Sahin L, Tassinari MS, Anderson PO, Baker TE et al (2017) Evaluation of the safety of drugs and biological products used during lactation: workshop summary. Clin Pharmacol Ther 101(6):736\u2013744","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"858_CR102","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1124\/mol.109.056705","volume":"76","author":"DJ Waxman","year":"2009","unstructured":"Waxman DJ, Holloway MG (2009) Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 76(2):215\u2013228","journal-title":"Mol Pharmacol"},{"issue":"4","key":"858_CR103","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/hep.1840380424","volume":"38","author":"R Wolbold","year":"2003","unstructured":"Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M et al (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38(4):978\u2013988","journal-title":"Hepatology"},{"issue":"8","key":"858_CR104","volume":"18","author":"ND Wood","year":"2024","unstructured":"Wood ND, Smith D, Kinrade SA, Sullivan MT, Rayner CR, Wesche D et al (2024) The use of quantitative clinical pharmacology approaches to support moxidectin dosing recommendations in lactation. PLoS Negl Trop Dis 18(8):e0012351","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"858_CR105","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/ki.2013.399","volume":"85","author":"CK Yeung","year":"2014","unstructured":"Yeung CK, Shen DD, Thummel KE, Himmelfarb J (2014) Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int 85(3):522\u2013528","journal-title":"Kidney Int"},{"issue":"1","key":"858_CR106","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/jpet.116.233635","volume":"358","author":"HF Zhang","year":"2016","unstructured":"Zhang HF, Wang HH, Gao N, Wei JY, Tian X, Zhao Y et al (2016) Physiological content and intrinsic activities of 10 cytochrome P450 isoforms in human Normal liver Microsomes. J Pharmacol Exp Ther 358(1):83\u201393","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"858_CR107","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tox.2009.08.013","volume":"278","author":"SF Zhou","year":"2010","unstructured":"Zhou SF, Zhou ZW, Huang M (2010) Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 278(2):165\u2013188","journal-title":"Toxicology"},{"issue":"9","key":"858_CR108","first-page":"475","volume":"5","author":"W Zhou","year":"2016","unstructured":"Zhou W, Johnson TN, Xu H, Cheung SYA, Bui KH, Li J et al (2016) Predictive performance of physiologically based pharmacokinetic and population pharmacokinetic modeling of Renally cleared drugs in children. CPT: Pharmacometr Syst Pharmacol 5(9):475\u2013483","journal-title":"CPT: Pharmacometr Syst Pharmacol"},{"issue":"1","key":"858_CR109","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/cpt.905","volume":"104","author":"W Zhou","year":"2018","unstructured":"Zhou W, Johnson TN, Bui KH, Cheung SYA, Li J, Xu H et al (2018) Predictive performance of physiologically based pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children. Clin Pharmacol Ther 104(1):188\u2013200","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"858_CR110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40246-023-00461-z","volume":"17","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Nevosadova L, Eliasson E, Lauschke VM (2023) Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences. Hum Genomics 17(1):15","journal-title":"Hum Genomics"}],"container-title":["Handbook of Experimental Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2026_858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:38:43Z","timestamp":1790192323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2026_858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":110,"URL":"https:\/\/doi.org\/10.1007\/164_2026_858","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"24 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}